IFNγ-IL12 axis regulates intercellular crosstalk in metabolic dysfunction-associated steatotic liver disease
-
Published:2024-06-29
Issue:1
Volume:15
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Friedline Randall H.ORCID, Noh Hye Lim, Suk Sujin, Albusharif Mahaa, Dagdeviren SezinORCID, Saengnipanthkul SuchaornORCID, Kim Bukyung, Kim Allison M., Kim Lauren H., Tauer Lauren A.ORCID, Baez Torres Natalie M., Choi Stephanie, Kim Bo-Yeon, Rao Suryateja D., Kasina Kaushal, Sun Cheng, Toles Benjamin J., Zhou ChanORCID, Li Zixiu, Benoit Vivian M., Patel Payal R., Zheng Doris X. T., Inashima Kunikazu, Beaverson Annika, Hu Xiaodi, Tran Duy A., Muller WernerORCID, Greiner Dale L., Mullen Alan C.ORCID, Lee Ki Won, Kim Jason K.ORCID
Abstract
AbstractObesity is a major cause of metabolic dysfunction-associated steatohepatitis (MASH) and is characterized by inflammation and insulin resistance. Interferon-γ (IFNγ) is a pro-inflammatory cytokine elevated in obesity and modulating macrophage functions. Here, we show that male mice with loss of IFNγ signaling in myeloid cells (Lyz-IFNγR2−/−) are protected from diet-induced insulin resistance despite fatty liver. Obesity-mediated liver inflammation is also attenuated with reduced interleukin (IL)−12, a cytokine primarily released by macrophages, and IL-12 treatment in vivo causes insulin resistance by impairing hepatic insulin signaling. Following MASH diets, Lyz-IFNγR2−/− mice are rescued from developing liver fibrosis, which is associated with reduced fibroblast growth factor (FGF) 21 levels. These results indicate critical roles for IFNγ signaling in macrophages and their release of IL-12 in modulating obesity-mediated insulin resistance and fatty liver progression to MASH. In this work, we identify the IFNγ-IL12 axis in regulating intercellular crosstalk in the liver and as potential therapeutic targets to treat MASH.
Funder
U.S. Department of Health & Human Services | NIH | Center for Information Technology U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
Publisher
Springer Science and Business Media LLC
Reference99 articles.
1. Byrne, C. D. & Targher, G. NAFLD: a multisystem disease. J. Hepatol. 62, S47–S64 (2015). 2. Younossi, Z. M. Non-alcoholic fatty liver disease - A global public health perspective. J. Hepatol. 70, 531–544 (2019). 3. Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84 (2016). 4. Li, H. et al. Crosstalk between liver macrophages and surrounding cells in nonalcoholic steatohepatitis. Front Immunol. 11, 1169 (2020). 5. Dewidar, B., Kahl, S., Pafili, K. & Roden, M. Metabolic liver disease in diabetes - From mechanisms to clinical trials. Metabolism 111S, 154299 (2020).
|
|